Cantor Fitzgerald
CAMP icon

Cantor Fitzgerald’s CAMP4 Therapeutics CAMP Stock Holding History

Cantor Fitzgerald’s Portfolio CAMP Stock Details CAMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$234K Buy
+53,500
New +$231K ﹤0.01% 314
2025
Q3 		– Sell
-12,320
Closed -$17.9K – 401
2025
Q2 		$17.9K Buy
+12,320
New +$24.5K ﹤0.01% 409

Other funds holding CAMP

Jupiter Topco
Jupiter Topco New York $245B AUM
5AM Venture Management
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vivo Capital
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
AH Capital Management
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Trails Edge Capital Partners
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Cantor Fitzgerald's CAMP Position: Q2 2026 in Review

Cantor Fitzgerald opened a new position in CAMP4 Therapeutics (CAMP) in Q2 2026: 53,500 shares worth $234K. The stake represents ﹤0.01% of the portfolio and ranks #314 among its holdings. This is a return to the name: Cantor Fitzgerald previously reported a position in CAMP as recently as Q2 2025.

Cantor Fitzgerald first reported a position in CAMP in Q2 2025 and has held it in 2 quarters since. 61 funds tracked by Wall St. Rank hold CAMP as of Q2 2026.

  • Cantor Fitzgerald held 53,500 shares of CAMP4 Therapeutics worth $234K as of Q2 2026.
  • CAMP4 Therapeutics was a new Cantor Fitzgerald position in Q2 2026.
  • CAMP4 Therapeutics made up ﹤0.01% of Cantor Fitzgerald's portfolio in Q2 2026, its #314 holding.
  • Cantor Fitzgerald first reported a position in CAMP4 Therapeutics in Q2 2025 and has held it in 2 quarters since.
  • 61 funds tracked by Wall St. Rank held CAMP4 Therapeutics as of Q2 2026.

Based on Cantor Fitzgerald's 13F filing for Q2 2026, filed 14 Aug 2026.